Inozyme Pharma Inc (NASDAQ: INZY) established initial surge of 4.54% at $4.61, before settling in for the price of $4.41 at the close. Taking a more long-term approach, INZY posted a 52-week range of $2.69-$7.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was -35.73%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -7.78%. This publicly-traded company’s shares outstanding now amounts to $61.77 million, simultaneously with a float of $41.14 million. The organization now has a market capitalization sitting at $284.76 million. At the time of writing, stock’s 50-day Moving Average stood at $5.73, while the 200-day Moving Average is $4.71.
Inozyme Pharma Inc (INZY) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Inozyme Pharma Inc industry. Inozyme Pharma Inc’s current insider ownership accounts for 33.41%, in contrast to 58.13% institutional ownership. According to the most recent insider trade that took place on Apr 02 ’24, this organization’s CEO sold 7,523 shares at the rate of 6.94, making the entire transaction reach 52,210 in total value, affecting insider ownership by 20,665. Preceding that transaction, on Aug 01 ’23, Company’s Director bought 833,333 for 4.80, making the whole transaction’s value amount to 3,999,998. This particular insider is now the holder of 2,923,110 in total.
Inozyme Pharma Inc (INZY) Earnings and Revenue Records
Inozyme Pharma Inc’s EPS decrease for this current 12-month fiscal period is -7.78% and is forecasted to reach -1.60 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.10% through the next 5 years, which can be compared against the -35.73% growth it accomplished over the previous five years trading on the market.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Let’s observe the current performance indicators for Inozyme Pharma Inc (INZY). It’s Quick Ratio in the last reported quarter now stands at 13.36. The Stock has managed to achieve an average true range (ATR) of 0.37.
In the same vein, INZY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.39, a figure that is expected to reach -0.36 in the next quarter, and analysts are predicting that it will be -1.60 at the market close of one year from today.
Technical Analysis of Inozyme Pharma Inc (INZY)
Now, what If we examine the latest scores posted by [Inozyme Pharma Inc, INZY]. During the last 5-days, its volume was lower the volume of 0.62 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 48.77% While, its Average True Range was 0.32.
Raw Stochastic average of Inozyme Pharma Inc (INZY) in the period of the previous 100 days is set at 26.19%, which indicates a major fall in contrast to 41.75% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.93% that was lower than 71.01% volatility it exhibited in the past 100-days period.
